ChemicalBook > Product Catalog >API >Drugs Influencing Immune Function >Immunosuppressive drugs >Rapamycin


Rapamycin Suppliers list
Company Name: Shanghai Arbor Chemical Co., Ltd.
Tel: 021-60451682
Products Intro: Product Name:Rapamycin
Purity:97% Package:10G 100G 1KG 25KG
Company Name: Beijing Yibai Biotechnology Co., Ltd
Tel: 0086-182-6772-3597
Products Intro: Product Name:Rapamycin Sirolimus
Purity:99% Package:1g;USD|1KG;USD|10KG;USD
Tel: +86 18953170293
Products Intro: Product Name:Sirolimus
Purity:0.99 Package:25kg/drum
Company Name: Xingtai pinmai biology science and technology co., ltd
Tel: +8618633865755
Products Intro: Product Name:Sirolimus
Purity:99.99% Package:1g;1USD
Company Name: Capot Chemical Co.,Ltd.
Tel: +86-571-85586718
Products Intro: Product Name:Rapamycin
Purity:98% (Min,GC) Package:100g;1kg;5kg,10kg,25kg,50kg

Lastest Price from Rapamycin manufacturers

  • Sirolimus
  • US $0.00 / kg
  • 2020-10-21
  • CAS:53123-88-9
  • Min. Order: 5g
  • Purity: 98
  • Supply Ability: 100kg
  • rapamycin 53123-88-9
  • US $110.00 / g
  • 2020-08-17
  • CAS:53123-88-9
  • Min. Order: 1g
  • Purity: ≥98%
  • Supply Ability: 1000.00 kgs
  • Rapamycin Sirolimus
  • US $0.00-0.00 / KG
  • 2020-07-22
  • CAS:53123-88-9
  • Min. Order: 1g
  • Purity: 99%
  • Supply Ability: 50kg/month

Related articles

  • What is Rapamycin?
  • Sirolimus, also known as rapamycin, is a macrolide derived from Streptomyces hygroscopicus. Sirolimus and its analog molecules....
  • Feb 10,2020
Rapamycin Basic information
Indications and Usage Mechanisms of Action Application Adverse reactions
Product Name:Rapamycin
Product Categories:VIVACTIL;antibiotic;Inhibitor;Chiral Reagents;Heterocycles;11;API;Signalling;Immunosuppressant;All Inhibitors;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals;Cytokine signaling;Active Pharmaceutical Ingredients
Mol File:53123-88-9.mol
Rapamycin Structure
Rapamycin Chemical Properties
Melting point 183-185°C
alpha D25 -58.2° (methanol)
Boiling point 799.83°C (rough estimate)
density 1.0352 (rough estimate)
vapor pressure 0.56 hPa ( 20 °C)
refractive index 1.5280 (estimate)
Fp 87 °C
storage temp. -20°C
solubility ethanol: soluble2MM
form solution
color colorless to yellow
Water Solubility Soluble in DMSO at 50mg/ml or methanol at 25mg/mlSoluble in alcohol, dimethyl sulfoxide and dimethyl formamide. Insoluble in water.
Sensitive Moisture Sensitive/Light Sensitive/Hygroscopic
Merck 14,8114
CAS DataBase Reference53123-88-9(CAS DataBase Reference)
Safety Information
Hazard Codes Xi,Xn,F
Risk Statements 36/38-36-20/21/22-11
Safety Statements 22-24/25-37/39-26-36/37-16
WGK Germany 2
RTECS VE6250000
Autoignition Temperature301 °C
HS Code 29349990
Hazardous Substances Data53123-88-9(Hazardous Substances Data)
ToxicityLD50 in mice (mg/kg): 600 i.p.; >2,500 orally (Vézina)
MSDS Information
Sirolimus English
Rapamycin Usage And Synthesis
Indications and UsageRapamycin (Rapa, or Sirolimus) is a new form of macrolide immunosuppressive agent. It is a white solid crystal. Its melting point is 183-185℃ and it is lipophilic. It is soluble in methanol, ethanol, acetone, chloroform, and other organic solvents, very slightly soluble in water, and almost insoluble in ether. It was first discovered in 1975 on the Chilean Easter Island as a secondary metabolite secreted by soil Streptomyces, and its chemical structure is that of a three-polyene macrolide compound.
Rapamycin is a new form of immunosuppressive agent with good curative effects, low toxicity, and no nephrotoxicity. It can be used to maintain the immunity of transplant organs (especially in kidney transplants) to alleviate immunological rejections after organ transplant surgeries. The latest research has shown that Rapamycin can also be used to treat Alzheimer’s. When used on afflicted lab rats, it had a memory-restoring effect. Rapamycin oral tablets can be taken with grapefruit juice to treat melanoma (a type of benign tumor common among Western populations), dramatically increase other chemotherapy drugs’ anticancer effects, and extend patient survival. Rapamycin is a mammalian target of rapamycin (mTOR) targeting inhibitor, which can treat tumors that are related to this pathway including kidney cancer, lymphoma, lung cancer, liver cancer, breast cancer, neuroendocrine carcinoma, gastric cancer, etc. Its curative effects are especially strong for the rare diseases LAM (lymphangiomyomatosis) and TSC (tuberous sclerosis).
Mechanisms of ActionRapamycin is a type of macrolide antibiotic and has a similar structure to Prograf (FK506), but has very different immunosuppressing mechanisms. FK506 suppresses T lymph cells from proliferating from G0 to G1 stage, while RAPA uses different cytokine receptors to block signal transduction, thus preventing T lymph cells and other cells from proliferating from G1 to S stage. Compared to Prograf, Rapamycin can block the signal transduction pathways of the calcium dependency and calcium non-dependency of T lymph cells and B lymph cells.

As an mTOR inhibitor, sirolimus has a broad spectrum of activity that has demonstrated the ability to inhibit inflammation, proliferation, angiogenesis, fibrosis, and hyperpermeability. Sirolimus currently has multiple uses in the prevention of rejection in organ transplantation and, recently, in the treatment of advanced renal cell carcinoma. Sirolimus-eluting cardiac stents have been shown to limit the rate of overgrowth of tissue and thus prevent coronary restenosis. Early studies suggest that it may be an effective agent for controlling severe uveitis and that it may also have a role in treating agerelated macular degeneration.

Adverse reactionsRapamycin has similar side effects to those of Prograf. Many clinical trials have found that its side effects are dose dependent and reversible. A treatment dosage of Rapamycin has not been found to lead to any significant nephrotoxicity or gingival hyperplasia. Its main toxic side effects include: headache, nausea, dizziness, nosebleed, and join pain. Laboratory inspections for anomalies found: thrombocytopenia, decreased white blood cells, decreased hemoglobin, hypertriglyceridemia, hypercholesterolemia, hyperglycemia, increased liver enzymes (SGOT, SGPT), increased lactate dehydrogenase, hypokalemia, hypokalemia, etc. Rapamycin may lead to puffiness of eyelids and lead to lowered plasma phosphate levels. Similar to other immunosuppressants, Rapamycin may also increase the chance of infection, with reports of increased tendency towards pneumonia.
Chemical PropertiesWhite to Off-White Solid
OriginatorRapamune,Wyeth Laboratories,UK
UsesTool for immunochemistry.
UsesA specific mTOR inhibitor with an IC50 of 0.1 nM.
Usesimmunosuppressant, antineoplastic; rapamycin
UsesRapamycin is a triene macrolide discovered in 1995 as a metabolite of Streptomyces hygroscopicus found in a soil obtained on Rapi Nui (Easter Island). Rapamycin displayed potent and selective antifungal activity, notably against Candida albicans. Interest in the metabolite waned until the structural relationship to the potent immunosuppressant fujimycin (Antibiotic FK506) was recognised in the mid-1980s. This recognition led to the re-discovery of rapamycin as a highly selective antitumour and immunosuppressant. Rapamycin inhibits the activity of the protein, mTOR (mammalian target of rapamycin) which functions in a signalling pathway to promote tumour growth. Rapamycin binds to a receptor protein (FKBP12). The rapamycin/FKB12 complex then binds to mTOR and prevents interaction of mTOR with target proteins in this signalling pathway.
UsesDDP-4 inhibitor type 2 diabetes therapeutic
UsesRapamycin is a triene macrolide discovered in 1974 as a metabolite of Streptomyces hygroscopicus found in a soil obtained on Rapa Nui (Easter Island). Rapamycin displayed potent and selective antifungal activity, notably against Candida albicans. Interest in the metabolite waned until the structural relationship to the potent immunosuppressant fujimycin (Antibiotic FK506) was recognised in the mid-1980s. This recognition led to the re-discovery of rapamycin as a highly selective antitumor and immunosuppressant. Rapamycin inhibits the activity of the protein, mTOR (mammalian target of rapamycin) which functions in a signalling pathway to promote tumor growth. Rapamycin binds to a receptor protein (FKBP12). The rapamycin/FKB12 complex then binds to mTOR and prevents interaction of mTOR with target proteins in this signalling pathway.
UsesLabelled Rapamycin. A triene macrolide antibiotic isolated from Streptomyces hygroscopicus. Name derived from the native word for Easter Island, Rapa?Nui. Used as an immunosuppressant; antirestenotic. This compound contains aproximately 2% d0.;Labeled Sir
UsesRapamycin is an immunosuppressant that is used primarily to prevent the rejection of organ and bone marrow transplant. It was first described as a potent inhibitor of IL-2 activation of lymphocytes (IC50 = 5 pM). It is now known that rapamycin specifically interacts with the cytosolic FK-binding protein 12 (FKBP12) to form a complex which inhibits the mammalian target of rapamycin (mTOR) pathway by directly binding to mTOR Complex 1 (mTORC1). Rapamycin and other inhibitors of mTORC1 signaling show potential in treating cancer, adipogenesis, diabetes, tuberous sclerosis, and cardiovascular disease.[Cayman Chemical]
DefinitionChEBI: A macrolide isolated from Streptomyces hygroscopicus consisting of a 29-membered ring containing 4 trans double bonds, three of which are conjugated. It is an antibiotic, immunosupressive and antineoplastic agent.
IndicationsMechanistic target of rapamycin (mTOR) is a serine/threonine-specific protein kinase in the PI3/PI4-kinase family. mTOR was named after the natural macrolide rapamycin, also known as sirolimus, which was isolated from a soil sample from Easter Island in the 1970s and later evaluated as an immunosuppressive agent. The anticancer activity of rapamycin was discovered in the 1980s, although the mechanismof action and the identification of the rapamycin target, mTOR, were not elucidated until the 1990s. Rapamycin and its macrocyclic analogues, such as temsirolimus (Torisel(R), Wyeth/Pfizer) and everolimus (Afinitor(R), Novartis), are grouped as “rapalogs” that constitute the first-generation mTOR inhibitors.
Rapamycin was approved by the US FDA in 1999 as an immunosuppressive agent to prevent organ rejection in patients receiving kidney transplants. Although a large number of clinical studies have been performed to evaluate the anticancer activities of sirolimus in different types of cancers, such as invasive bladder cancer, breast cancer, and leukemia, most studies show limited efficacy. Outside oncological indications, sirolimus was approved by FDA for the treatment of a rare progressive lung disease lymphangioleiomyomatosis in 2015. Temsirolimus was approved for the treatment of advanced RCC. Everolimus was approved in the EU for the prevention of organ rejection in heart and kidney transplant recipients before FDA approved it in 2009 for the treatment of advanced RCC resistant to sunitinib or sorafenib and for the treatment of advanced or metastatic gastrointestinal and lung tumors in 2016. Additionally, rapamycin and rapalogs are being investigated as antiaging therapeutics or for the treatment of age-related diseases. Studies have revealed that mTOR activity can be retained under hypoxic conditions via mutations in the PI3K pathway, leading to increased translation and hypoxic gene expression and tumor progression.
IndicationsSirolimus (Rapamune) is structurally related to tacrolimus. It is approved for use as an adjunctive agent in combination with cyclosporine for prevention of acute renal allograft rejection. It blocks IL-2-dependent T-cell proliferation by inhibiting a cytoplasmic serine– threonine kinase. This mechanism of action is different from those of tacrolimus and cyclosporine. This allows sirolimus to augment the immunosuppressive effects of these drugs.
Manufacturing ProcessStreptomyces hygroscopicus NRRL 5491 was grown and maintained on oatmeal-tomato paste agar slants (T. G. Pridham et al.; Antibiotic Annual 1956-1957, Medical Encyclopedia Inc., New York, p. 947) and in Roux bottles containing the same medium. Good growth was obtained after 7 days of incubation at 28°C. Spores from one Roux bottle were washed off and suspended into 50 ml of sterile distilled water. This suspension was used to inoculate the first stage inoculum.The first-stage inoculum medium consisted of Emerson broth [R. L. Emerson et al., J. Bacteriol, 52, 357 (1946)] 0.4% peptone, 0.4% sodium chloride, 0.25% yeast extract and 1% glucose; pH 7.0; flasks containing the above medium were inoculated with 1 % of the spore suspension described above. The inoculated flasks were incubated for 30 hours at 28°C on a reciprocating shaker set at 65 r.p.m. (4 inch stroke).
Production stage
The production stage was run in 250-liter New Brunswick fermenters Model F- 250, equipped with automatic antifoam addition system and pH recordercontroller. The fermenters were charged with 160 L of an aqueous production medium consisting of the following constituents: 1.0% soluble starch; 0.5% (NH4)2SO4; 0.5% K2HPO4; 1.5% glucose (Cerelose); 0.025% MgSO4; 0.005% ZnSO4; 0.001% MnSO4; 0.002% FeSO47H2O; 0.2% CaCO3; 0.5% "Blackstrap" molasses; 0.5% hydrolyzed casein; 0.2% lard oil; pH 7.1 to 7.3 of first stage inoculum. Incubation temperature: 28°C; aeration: 0.5 vol/vol/min; agitation: 250 r.p.m. The fermenters were sterilized at 121°C for 45 min, cooled and inoculated with one flask inoculum).
A titre of ca. 20 μg/ml, determined by microbiological assay on agar plates seeded with Candida albicans, was reached in 5 days. The fermentation was stopped. The fermentation mixture was extracted twice with 1 v/v of nbutanol. The combined butanol extracts were washed with 1 v/v of water, dried with anhydrous sodium sulfate and evaporated to dryness under reduced pressure to yield a residue. The oily residue was extracted 3 times with 2 L of methanol. The combined methanol extracts were passed through diatomaceous earth (Celite) and evaporated to dryness to yield an oily residue containing crude Rapamycin.
Brand nameRapamune (Wyeth).
Therapeutic FunctionImmunosuppressive, Antifungal
Biological ActivityAntifungal and immunosuppressant. Specific inhibitor of mTOR (mammalian target of Rapamycin). Complexes with FKBP-12 and binds mTOR inhibiting its activity. Inhibits interleukin-2-induced phosphorylation and activation of p70 S6 kinase.
Rapamycin Preparation Products And Raw materials
Tag:Rapamycin(53123-88-9) Related Product Information
NA Mycophenolate mofetil Azithromycin POLYOXIN B Zopiclone NA SECO RAPAMYCIN SODIUM SALT RAPAMYCIN [3H(G)] mTOR, phosphorylated (pSer2481) (mTAb1, Mammalian Target of Rapamycin, FRAP, RAFT) (42S)-42-Deoxy-42-(1H-tetrazol-1-yl)rapamycin mTOR, phosphorylated (Ser2448) (mTAb1, Mammalian Target of Rapamycin, FRAP, RAFT) ANTI-MAMMALIAN TARGET OF RAPAMYCIN,ANTI-FKBP-12 RAPAMYCIN ASSOCIATED PROTEIN 42-O-(2-Hydroxyethyl-d4)rapamycin RAPAMYCIN ASSOCIATED PROTEIN FRAP2 FRAGMENT BIOTINYL/AMIDE rapamycin tris-epoxide metabolite mTOR, aa2433-2450 (mTAb1, Mammalian Target of Rapamycin, FRAP, RAFT) RAPAMYCIN [32 METHOXY-3H] Rapamycin 42-[3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate